⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Jiangsu Carephar Pharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Jiangsu Carephar Pharmaceutical Co., Ltd.
↗Nanjing, China
Jiangsu Carephar Pharmaceutical Co., Ltd. is an innovative, research-driven pharmaceutical company established in 2006. The company specializes in the discovery, development, and commercialization of high-clinical-value drugs, with a primary focus on cardiovascular, cerebrovascular, and digestive system disorders, as well as tumor immunotherapy.
Carephar maintains a fully integrated industrial chain, encompassing R&D, production, and sales. The company operates multiple R&D centers and production bases, utilizing core technologies such as plant-derived medicinal monomer modification, P-CAB (potassium-competitive acid blocker) development, and high-selectivity small molecule targeted drug design.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Cardiovascular and Digestive Therapeutics
SIZE & FINANCIALS
Employees:201-500
Founded:2006
Ownership:private
Status:operating
FUNDING
Stage:Private
PIPELINE
Stage:Phase 3
Lead Drug Stage:Commercial/Phase 3
Modalities:Small molecule, Mesenchymal stem cell therapy
Active Trials:55
Trial Phases:Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Global collaboration for Keverprazan Hydrochloride)
COMPETITION
Position:Niche Player
Competitors:argenx, Tenaya Therapeutics, Vor Biopharma
LINKS
Website:carephar.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Jiangsu Carephar Pharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.